JAMA Network
About The Study: Among adults age 60 years and older in 19 U.S. states, respiratory syncytial virus (RSV) vaccination was associated with a reduced likelihood of hospitalization with RSV compared with no vaccination. These findings expand upon prelicensure trial results in 2 ways. First, they provide evidence of vaccine protection against RSV-associated hospitalization, of which an estimated 60,000 to 160,000 occur annually among U.S. adults age 65 years and older. Second, they demonstrate protection in a population that more closely represents those at high risk of severe RSV disease, including adults age 75 years and older and those with immunocompromising conditions.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.